{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T12:15:28Z","timestamp":1772540128278,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T00:00:00Z","timestamp":1471910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014389","name":"Amarin Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014389","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","atherosclerosis-journal.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.atherosclerosis.2016.08.005","type":"journal-article","created":{"date-parts":[[2016,8,23]],"date-time":"2016-08-23T08:37:34Z","timestamp":1471941454000},"page":"81-87","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies"],"prefix":"10.1016","volume":"253","author":[{"given":"Christie M.","family":"Ballantyne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold E.","family":"Bays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5329-8125","authenticated-orcid":false,"given":"Sephy","family":"Philip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Ralph T.","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rene A.","family":"Braeckman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G.","family":"Stirtan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paresh N.","family":"Soni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca A.","family":"Juliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.pharmthera.2013.11.008","article-title":"Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment","volume":"141","author":"Varbo","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib2","doi-asserted-by":"crossref","first-page":"e655","DOI":"10.1161\/CIRCULATIONAHA.113.005954","article-title":"Letter by Jones et\u00a0al regarding article, \u201cElevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation\u201d","volume":"129","author":"Jones","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib3","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib4","doi-asserted-by":"crossref","first-page":"A1569","DOI":"10.1016\/S0735-1097(15)61569-8","article-title":"Cholesterol in remnant-lipoproteins as measured by different methods [abstract]","volume":"65","author":"Toth","year":"2015","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib5","doi-asserted-by":"crossref","first-page":"e656","DOI":"10.1161\/CIRCULATIONAHA.114.009348","article-title":"Reply to letters regarding article, \u201celevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"129","author":"Varbo","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.atherosclerosis.2011.04.040","article-title":"Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals","volume":"218","author":"Nakamura","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib7","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1253\/circj.CJ-14-0380","article-title":"High remnant lipoprotein predicts recurrent cardiovascular events on statin treatment after acute coronary syndrome","volume":"78","author":"Nguyen","year":"2014","journal-title":"Circ. J."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib8","article-title":"Remnant lipoproteinemia predicts cardiovascular events in patients with type 2 diabetes and chronic kidney disease","author":"Nguyen","year":"2016","journal-title":"J.\u00a0Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib9","article-title":"Remnant lipoprotein cholesterol and incident coronary heart disease: the jackson heart and framingham offspring cohort studies","volume":"5","author":"Joshi","year":"2016","journal-title":"J.\u00a0Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1373\/clinchem.2015.253757","article-title":"Increased remnant cholesterol explains part of residual risk of all-cause mortality in 5414 patients with ischemic heart disease","volume":"62","author":"Jepsen","year":"2016","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/VHRM.S104369","article-title":"Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease","volume":"12","author":"Toth","year":"2016","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib12","unstructured":"Vascepa [package insert], Bedminster, NJ, Amarin Pharma Inc., 2015."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib14","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib15","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report","volume":"106","author":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/ATVBAHA.107.157123","article-title":"Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women","volume":"28","author":"Lamon-Fava","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib17","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1093\/clinchem\/44.6.1224","article-title":"Remnant lipoprotein cholesterol and triglyceride reference ranges from the Framingham Heart Study","volume":"44","author":"McNamara","year":"1998","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0009-8981(93)90062-9","article-title":"Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels","volume":"223","author":"Nakajima","year":"1993","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.plefa.2013.07.005","article-title":"Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)","volume":"89","author":"Braeckman","year":"2013","journal-title":"Prostagl. Leukot. Essent. Fat. Acids"},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2005.01.012","article-title":"Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome","volume":"181","author":"Nakamura","year":"2005","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib22","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1161\/CIRCULATIONAHA.113.003008","article-title":"Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation","volume":"128","author":"Varbo","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jacl.2014.02.036","article-title":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the MARINE and ANCHOR studies [abstract 122]","volume":"8","author":"Ballantyne","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jacl.2014.11.009","article-title":"Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)","volume":"9","author":"Ballantyne","year":"2015","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib25","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","article-title":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary","volume":"8","author":"Jacobson","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1475-2840-12-100","article-title":"Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200\u2013500 mg\/dL), and on statin therapy at LDL-C goal: the ANCHOR study","volume":"12","author":"Brinton","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib28","first-page":"311","article-title":"Effects of eicosapentaenoic acids on remnant-like particles, cholesterol concentrations and plasma fatty acid composition in patients with diabetes mellitus","volume":"12","author":"Nakamura","year":"1998","journal-title":"In\u00a0Vivo"},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib29","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1681\/ASN.V10102177","article-title":"Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in\u00a0vivo peroxidation of LDL in dialysis patients","volume":"10","author":"Ando","year":"1999","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2337\/dc06-1179","article-title":"Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome","volume":"30","author":"Satoh","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacl.2009.08.001","article-title":"Effects of prescription omega-3 ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia","volume":"3","author":"Davidson","year":"2009","journal-title":"J.\u00a0Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.4065\/mcp.2009.0397","article-title":"Effects of prescription omega-3-acid ethyl esters on non\u2013high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin","volume":"85","author":"Bays","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib34","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1373\/clinchem.2015.241752","article-title":"Identifying an optimal cut point for the diagnosis of hypertriglyceridemia in the nonfasting state","volume":"61","author":"White","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacc.2012.11.009","article-title":"Remnant cholesterol: \u201cNon-(HDL-C\u00a0+ LDL-C)\u201d as a coronary artery disease risk factor","volume":"61","author":"McPherson","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib36","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1161\/ATVBAHA.114.305172","article-title":"Triglyceride-rich lipoproteins and coronary artery disease risk: new insights from human genetics","volume":"35","author":"Khetarpal","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib37","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1194\/jlr.R700001-JLR200","article-title":"Remnant-like lipoprotein particles impair endothelial function: direct and indirect effects on nitric oxide synthase","volume":"48","author":"Zheng","year":"2007","journal-title":"J.\u00a0Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib38","doi-asserted-by":"crossref","first-page":"783","DOI":"10.5551\/jat.26328","article-title":"Impact of remnant lipoprotein on coronary plaque components","volume":"22","author":"Matsuo","year":"2015","journal-title":"J.\u00a0Atheroscler. Thromb."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib39","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib40","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1161\/ATVBAHA.114.305012","article-title":"Ezetimibe: rescued by randomization (clinical and Mendelian)","volume":"35","author":"McPherson","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib41","series-title":"A\u00a0Study of AMR101 to Evaluate its Ability to Reduce Cardiovascular Events in High Risk Patients with Hypertriglyceridemia and on Statin (REDUCE-IT)","year":"2015"},{"key":"10.1016\/j.atherosclerosis.2016.08.005_bib42","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1586\/14779072.6.3.391","article-title":"Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications","volume":"6","author":"Bays","year":"2008","journal-title":"Expert Rev. Cardiovasc. Ther."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016312540?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915016312540?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T08:23:22Z","timestamp":1668587002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915016312540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":42,"alternative-id":["S0021915016312540"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.08.005","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}